Abstract
A single injection of the long-acting antibody (LAAB) drug Evusheld (AZD7442) significantly reduced the risk of symptomatic COVID-19 infection for six months in immunocompromised patients, the drug’s manufacturer AstraZeneca has said. Evusheld is a combination of two LAABs: tixagevimab (AZD8895) and cilgavimab (AZD1061), both of which are derived from white blood cells donated by patients […]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
